Literature DB >> 12010633

Cardiac contractile function is enhanced in isolated ventricular myocytes from growth hormone transgenic mice.

P B Colligan1, H M Brown-Borg, J Duan, B H Ren, J Ren.   

Abstract

Growth hormone (GH) plays a key role in cardiac growth and function. However, excessive levels of GH often result in cardiac dysfunction, which is the major cause of death in acromegalic patients. Transgenic mice with GH over-expression serve as useful models for acromegaly and exhibit impaired cardiac functions using echocardiography, similar to those of human acromegaly. However, the mechanism underscoring the impaired ventricular function has not been well defined. This study was designed to evaluate the cardiac excitation-contraction coupling in GH over-expressing transgenic mice at the single ventricular myocyte level. Myocytes were isolated from GH and age-matched wild-type mouse hearts. Mechanical properties were evaluated using an IonOptix MyoCam system. The contractile properties analyzed included peak shortening (PS), time-to-peak shortening (TPS) and time-to-90% relengthening (TR(90)), and maximal velocities of shortening/relengthening (+/-dL/dt). Intracellular Ca2+ properties were evaluated by fura-2. GH transgenic mice exhibited significantly increased body weights and enlarged heart and myocyte size. Myocytes from GH transgenic mice displayed significantly enhanced PS and+/-dL/dt associated with similar TPS and TR(90) compared with the wild-type littermates. Myocytes from GH transgenic mice displayed a similar resting intracellular Ca2+ level and Ca2+ removal rate but exhibited an elevated peak intracellular Ca2+ level compared with the wild-type group. Myocytes from both groups were equally responsive to increases in extracellular Ca2+ concentration and stimulating frequency. These results suggest that GH over-expression is associated with enhanced contractile function in isolated myocytes and that the impaired cardiac function observed in whole hearts may not be due to defects at the myocyte level.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010633     DOI: 10.1677/joe.0.1730257

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  6 in total

1.  Prolonged exposure to GH impairs insulin signaling in the heart.

Authors:  J G Miquet; J F Giani; C S Martinez; M C Muñoz; L González; A I Sotelo; R K Boparai; M M Masternak; A Bartke; F P Dominici; D Turyn
Journal:  J Mol Endocrinol       Date:  2011-08-30       Impact factor: 5.098

2.  Elevated systolic blood pressure in male GH transgenic mice is age dependent.

Authors:  Adam Jara; Chance M Benner; Don Sim; Xingbo Liu; Edward O List; Lara A Householder; Darlene E Berryman; John J Kopchick
Journal:  Endocrinology       Date:  2013-01-01       Impact factor: 4.736

3.  Cardiac-Specific Disruption of GH Receptor Alters Glucose Homeostasis While Maintaining Normal Cardiac Performance in Adult Male Mice.

Authors:  Adam Jara; Xingbo Liu; Don Sim; Chance M Benner; Silvana Duran-Ortiz; Yanrong Qian; Edward O List; Darlene E Berryman; Jason K Kim; John J Kopchick
Journal:  Endocrinology       Date:  2016-04-01       Impact factor: 4.736

4.  Deficiency of insulin-like growth factor 1 reduces sensitivity to aging-associated cardiomyocyte dysfunction.

Authors:  Qun Li; Asli F Ceylan-Isik; Ji Li; Jun Ren
Journal:  Rejuvenation Res       Date:  2008-08       Impact factor: 4.663

5.  Longstanding hyperthyroidism is associated with normal or enhanced intrinsic cardiomyocyte function despite decline in global cardiac function.

Authors:  Nathan Y Weltman; Dajun Wang; Rebecca A Redetzke; A Martin Gerdes
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

6.  A crucial role of activin A-mediated growth hormone suppression in mouse and human heart failure.

Authors:  Noritoshi Fukushima; Katsuhisa Matsuura; Hiroshi Akazawa; Atsushi Honda; Toshio Nagai; Toshinao Takahashi; Akiko Seki; Kagari M Murasaki; Tatsuya Shimizu; Teruo Okano; Nobuhisa Hagiwara; Issei Komuro
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.